key: cord-1048181-5qmqdr0o
authors: Palma, Marzia; Mulder, Tom A.; Österborg, Anders
title: BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects
date: 2021-07-01
journal: Front Immunol
DOI: 10.3389/fimmu.2021.686768
sha: 70c0c4dd6ad9a9a0adf8de1507618d7e7a449cdc
doc_id: 1048181
cord_uid: 5qmqdr0o

Bruton´s tyrosine kinase (BTK) inhibitor (BTKi)s block the B-cell receptor (BCR) signaling cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant and normal B cells. During the past decade, the clinical use of BTKis for the treatment of B-cell malignancies has exponentially grown, changing the treatment landscape for chronic lymphocytic leukemia (CLL) in particular. At present, three different covalent BTKis, ibrutinib, acalabrutinib and zanubrutinib, are FDA-approved and many new inhibitors are under development. Despite having remarkable selectivity for BTK, the first-in-class BTKi ibrutinib can also bind, with various affinities, to other kinases. The combined inhibition of BTK (“on-target” effect) and other kinases (“off-target” effect) can have additive or synergistic anti-tumor effects but also induce undesired side effects which might be treatment-limiting. Such “off-target” effects are expected to be more limited for second-generation BTKis. Moreover, the blockade of BCR signaling also indirectly affects the tumor microenvironment in CLL. Treatment with BTKis potentially impacts on both innate and adaptive immunity. Whether this affects infection susceptibility and vaccination efficacy requires further investigation. Here, we summarize the available knowledge on the impact of BTKis on the immune system and discuss the possible clinical implications. Indeed, a deeper knowledge on this topic could guide clinicians in the management and prevention of infections in patients with CLL treated with BTKis.

Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of mature monoclonal CD5 + B lymphocytes in the secondary lymphoid organs, bone marrow and peripheral blood. Signaling through the B-cell receptor (BCR) is central in CLL and Bruton's tyrosine kinase (BTK) is a vital component of the BCR signaling pathway (1) . BTK inhibitor (BTKi)s block the BCR signaling cascade by binding to the BTK enzyme, hence preventing the proliferation and survival of malignant and normal B cells. Indeed, BTK is essential for the activation of pathways which promote lymphocyte survival, such as the nuclear factor kappaB (NF-kb) pathway (2) , and regulates chemokine secretion and B-cell adhesion by activation of phospholipase Cg2 (PLCg2) (3) .

The first-in-class BTKi ibrutinib, which inactivates BTK by binding covalently to cysteine 481 in the ATP-binding site of the enzyme in an irreversible manner, is FDA-approved for the treatment of CLL, mantle cell lymphoma (MCL), Waldenström's macroglobulinemia, marginal zone lymphoma, and graft-versushost disease. At present, two additional covalent BTKis, acalabrutinib and zanubrutinib, are FDA-approved for the treatment of MCL and CLL. Many new inhibitors, which bind reversibly, non-covalently, to the BTK are under development. The structure-function relationships of covalent and noncovalent BTKis are discussed by Zain et al. in the same issue of this journal.

In the past years, BTKis have been increasingly used for the treatment of B-cell malignancies, significantly changing the treatment algorithm for CLL in particular.

Despite having remarkable selectivity for BTK, ibrutinib can bind to other kinases with various affinities. Among these, interleukin-2-inducible T-cell kinase (ITK), which is highly expressed in T cells, and three epidermal growth factor receptor (EGFR) family kinases: EGFR, ErbB2/HER2 and ErbB4/HER4. The combined inhibition of BTK ("on-target" effect) and other kinases ("off-target" effect) can have additive or synergistic anti-tumor effects but also induce undesired side effects, such as atrial fibrillation (AF) and bleeding.

The two second-generation BTKis, acalabrutinib and zanubrutinib, were designed to more selectively bind to cysteine 481 in the kinase domain and therefore have less "offtarget" effects than ibrutinib. Phase 3 clinical trials are ongoing to compare the efficacy and toxicity profile of acalabrutinib and zanubrutinib with ibrutinib in CLL.

Besides "on-target" and "off-target" activity, there is, at least in CLL, convincing evidence that the anti-tumor effect of ibrutinib is related to the indirect effect that the blockade of the BCR-signaling has on the tumor microenvironment (TME) (4) . In CLL, the TME is supporting the tumor cell survival and growth by various mechanisms including triggering of BCR signaling and immune anergy, which leads to immune deficiency and susceptibility to infections. Treatment with BTKis potentially impacts on both innate and adaptive immunity, but to what extent this affects infection susceptibility in patients with CLL is still under investigation.

Here, we summarize the available knowledge on the biological activity of BTKis on immune cells, trying to dissect which of the effects can be attributed to BTK-inhibition itself ("on-target" activity), which indirectly result from BTK-inhibition suppressing the cross-talk within the TME ("on/off-target"), and which are truly due to the inhibition of kinases other than BTK ("off-target").

The active occupancy of the ATP-binding site of BTK by BTKis inhibits the subsequent phosphorylation of BTK, PLCg2, AKT and ERK abolishing the BCR signaling downstream of BTK both in vitro and in vivo. In CLL, the BCR signaling pathway is constitutively activated, in immunoglobulin heavy-chain variable (IGHV) mutated cases in particular (5) , and the anti-tumor effect of BTKis firstly depends on the direct inhibition of BTK (6) . Indeed, after inhibition of the BTK, pathways involved in CLL cells survival and expansion, such as the NF-kb pathway (7) as well as BAFF-R signaling (8) , cannot be activated. Chemokine secretion, specifically CCL3 and CCL4, and adhesion of B cells, is also inhibited (9) . The degree of BTK inhibition is traditionally measured by assessment of target occupancy, which has been evaluated in phase 1 studies. Available data suggest that sustained target occupancy during acalabrutinib treatment is necessary for the down-regulation of pathogenic pathways and to slow down BTK re-synthesis in CLL patients (10) . However, whether the degree of BTK occupancy impacts on the clinical outcome is still unknown.

Ibrutinib, the pioneer of BTKis, exhibits remarkable selectivity for BTK. However, its anti-tumor effect likely also depends on the indirect effect that the blockade of the BCR-signaling has on the TME ("on/off-target"). Indeed, the TME in CLL plays a major role in sustaining tumor cell survival and growth in the bone marrow and/or lymphoid tissues (11) . This is further supported by the limited direct pro-apoptotic activity observed when purified CLL cells are incubated in vitro with ibrutinib (12) , while apoptosis can be induced through mobilization of the leukemic cells from the lymph nodes in vivo (7, 13) . Upregulation of the survival protein Bcl-2, can be induced, as an example, by T cells through soluble factors such as IL-4 and IFN-g (14, 15) , or directly through CD40-CD40L interaction (16) , which is a key proliferative signal for CLL cells. Recently, it was shown that miRNAs can actively participate in the crosstalk between CLL cells and T cell signals and facilitate the co-occurrence of BCR and CD40 signaling activation (17) .

Chemokine receptors and adhesion molecules expressed on CLL cells are involved in the CLL-cell homing to the lymphoid organs. As an example, the CXCR4 chemokine receptor is highly expressed on the surface of CLL cells in the peripheral blood and mediates CLL cells chemotaxis and migration in response to CXCR4 ligand stromal cell-derived factor 1 (SDF-1a, CXCL12) produced by NLC. BCR engagement on CLL cells induces increased expression of these molecules (9) and it is therefore not surprising that BTK-inhibition by ibrutinib affects tumor cells-TME cells interactions, e.g. impairing CXCR4 signaling and therefore inhibiting cellular adhesion (18, 19) . Indeed, shortly after start of ibrutinib treatment, a temporary increase in the absolute lymphocyte count, so-called "redistribution lymphocytosis", is observed in patients with CLL (13, 20) , reflecting the release of tumor cells from the lymphoid organs to the peripheral blood (4). The downregulation of the CXCR4/CXCL12 axis also leads to the downregulation of both CD20 and of the anti-apoptotic protein Mcl1 in vivo (21) .

Finally, nine other kinases which have a corresponding cysteine residue in the ATP-binding site as BTK, are also likely affected by ibrutinib. These include four TFK members (ITK, TEC, BMX and RLK/TXK), three EGFR family kinases (EGFR, ErbB2/HER2 and ErbB4/HER4) and two other kinases, BLK and JAK3. The inhibition of these other kinases ("off-target" effect) can contribute to ibrutinib´s anti-tumor activity but also induce side effects which might be treatment-limiting.

Historically, the treatment of choice for CLL has been chemoimmunotherapy but the prognosis for high-risk patients, i.e. with relapsed/refractory (R/R) or del17p/TP53-mutated disease has been poor (22) . However, during the last decade targeted therapies including BTKis, B-cell lymphoma 2 (BCL2) antagonists and phosphoinositide 3-kinase (PI3K) inhibitors entered the therapeutic scene and significantly improved the overall outcome for patients with TP53 aberration and advanced-phase CLL (23) (24) (25) .

Ibrutinib is now a cornerstone in high-risk patients (23) and often recommended as first-line treatment particularly in IGHV unmutated cases in the US (26) (27) (28) . Overall response rates generally exceed 80% in trials and outside in both treatment-naïve and R/R patients but complete response rates are less than 10% (23, 27, 29, 30) . Treatment duration is indefinite, i.e. the patients stay on treatment until disease progression or unacceptable toxicity occurs. This latter, most commonly including AF, infections, pneumonitis, bleeding and diarrhea, led to treatment discontinuation in approximately 10% of the patients in clinical trials (31) .

Beyond its role in the development and functioning of B cells, BTK seems also to play a key role in innate immunity, being expressed in myeloid and other innate immune cells and regulating a number of immunological signaling networks within cells of the innate immune system (32) . Moreover, as mentioned above, the selectivity for BTK of ibrutinib in particular is far from being absolute, which can result in "off-target" effects on immune cells of both the innate and the adaptive immune system. Therefore, the immunomodulatory effects of BTKis can depend both on "ontarget" on immune cells other than B cells and "off-target" effects.

Ibrutinib seems to hamper the cytotoxic activity of NK cells (33) , while zanubrutinib does not seem to impair NK cell function to the same extent. This is most likely due to the inhibition of ITK by ibrutinib, which is much weaker with zanubrutinib, as demonstrated in patients with MCL (34) . ITK also mediates downstream signaling of the Fc receptor (FcR) (35) , which might explain why ibrutinib reduced antibody-dependent cellular cytotoxicity (ADCC) by NK cells (36) .

BTK is important for the development of neutrophils (37) and mediates signaling through Toll-like receptors and the FcR as well as activation of the NLRP3-inflammasome in macrophages (32, (38) (39) (40) and DC (41, 42) .

As the most potent antigen-presenting cells (APC), DC play a crucial role in bridging innate and adaptive immunity, thereby facilitating immunological memory, which is the cornerstone of vaccination. Hepatocyte growth factor (HGF) and T cell Ig and mucin protein-3 (TIM-3)-mediated BTK activity can suppress the NF-kB pathway in DC, which inhibits their activation and maturation (43, 44) . On the other hand, ibrutinib-treated DC have been shown to promote T-cell proliferation and drive a Th17 response (45) .

It has also been demonstrated that both ibrutinib and acalabrutinib reduce the phagocytosis and secretion of inflammatory cytokines by monocytes and macrophages in response to fungal stimuli (46, 47) , which could contribute to the susceptibility to invasive fungal infections (aspergillosis among others) observed in patients treated with ibrutinib (48) (49) (50) . Furthermore, ibrutinib seems to reduce the expression of chemotactic factors that tumor-infiltrating macrophages (TAM), or nurse-like cells (NLC) in CLL, use to attract and protect CLL cells (51) . Myeloid-derived suppressor cells (MDSC), another type of tumor-promoting myeloid cells, express BTK and it has been shown that ibrutinib blocks their development and immunosuppressive function (52) . It has been observed that the expression of PD-L1 on MDSC decreases during zanubrutinib treatment (53) .

Mast cells express BTK and other TEC family kinases (54) . BTK, ITK and TEC are important for the degranulation and cytokine production of mast cells upon FcR stimulation in mice (55, 56) and ibrutinib has also been shown to reduce these functions in human cells (38) . Although basophils and eosinophils are not so abundant, they play a significant role in the immune response against infections. The effect that BTKi might have on these cells deserves therefore to be studied more thoroughly.

Natural Killer T (NKT) cells and gd T cells combine features that are characteristic for innate and adaptive immunity. Innate lymphoid cells (ILC) are primarily tissue resident innate immune cells that descend from common lymphoid progenitors. Ibrutinib seems to hamper degranulation of gd T cells (57) . Even if relatively scarce, these cell types are important in the early response against pathogens. Whether they are influenced by BTKis is a largely uncharted territory of research.

Hypogammaglobulinemia is frequently observed in patients with CLL, with varying prevalence (20-70%) in different reports, and is more evident in progressive disease. Its severity correlates with infection risk (58) , thus justifying immunoglobulin (Ig) replacement therapy. The etiology of hypogammaglobulinemia is not elucidated, but likely due to a perturbation of the T cell/B cell interaction induced by the cancer cells (59) .

In the study by Sun et al., normal B cells seemed to increase over time during ibrutinib treatment, more significantly in treatment-naive patients compared to R/R ones. However, B-cell numbers remained abnormally low compared to healthy individuals. Despite the fact that BTK-deficiency in patients with X-linked agammaglobulinemia (XLA) leads to loss of circulating mature B cells and serum Igs, no significant decrease in IgG levels has been reported in patients during the first 6 months of ibrutinib treatment, while it became evident after 12 months (60). However, an increase of IgA levels over time has been reported by different studies (20, 29, 60) , so at least a partial reconstitution of humoral immunity seems to occur.

Abnormal T-cell subset distribution and function is known in CLL, partly correlating with tumor burden and previous anticancer treatment (61) . Skewing of the T-cell repertoire seems to occur early in the course of the disease, which has suggested that a positive selection of tumor-specific T-cell clones occurs (62) .

The effects of ibrutinib on the T-cell compartment have been reviewed by Mhibik et al. (63) . Even if the findings regarding the changes in T-cell numbers, including major subsets, during ibrutinib treatment have been controversial, with both reports on decrease (64, 65) and increase (66) , the available evidence seems to point out that T cells decrease in parallel with the reduction of the tumor burden (64, 65, 67) . Indeed, T cells are usually abnormally elevated in R/R CLL patients (61) , chronically activated by tumor antigens. This might explain why T cells initially remain stable or increase during the first weeks of treatment when persistent lymphocytosis is observed, and then decrease later. However, no decrease in CD4 + and CD8 + T-cell numbers was seen after treatment with either acalabrutinib (66, 68) or zanubrutinib (53) .

Proliferating T cells and expression of activation markers and immune checkpoints (PD-1, CTLA-4) also decreased both after treatment with ibrutinib (64, 65, 69) , acalabrutinib (68) and zanubrutinib (53) , also likely reflecting the decrease in tumor burden.

With regard to the T-cell receptor (TCR) diversity, discordant findings have been reported. In one study, an increase in TCR diversity was reported after 12 months of treatment ibrutinib with or without rituximab in patients with R/R CLL, positively correlating with clinical response and lower infection rates (67), while in another a more clonal repertoire was noted in patients responding to ibrutinib (70) .

In T cells, ITK is highly expressed and blocked by ibrutinib in a BTK-independent manner (71) . ITK plays a central role in Tcell maturation and differentiation into type 2 T-helper (Th2) effector cells. It has been shown that differentiation and migration of T cells to the lungs is compromised in ITKknockout mice (72) . By blocking ITK, ibrutinib has the potential to selectively decrease Th2 cell numbers causing Th1 skewing (69) . Indeed, several studies have reported the reduction of some Th2-cytokines in ibrutinib-treated patients (64, 66, 67, 73) . However, no change in Th1/Th2 polarization was observed in patients treated with acalabrutinib (66) or zanubrutinib (53) , supporting the idea that ITK inhibition is central in Th skewing. Moreover, a decrease in Th17 cells and related cytokines was also observed (64, 67) , as well as in the numbers of regulatory T cells (Tregs) in the first weeks of treatment (73) , which is also supposed to be mediated by ITK inhibition. An increase in Th17 cells number was also observed in R/R patients treated with both acalabrutinib (66) and zanubrutinib (53) . The immunomodulatory effects of BTKis are summarized in Table 1 .

In patients with CLL, recurrent infections are a major cause of morbidity and mortality. The high infection rate is due a number of immune defects inherent to the disease, consisting of hypogammaglobulinemia, abnormal T-cell function and neutropenia due to bone marrow infiltration, and further aggravated by cytopenias induced by CLL treatment (59) . Hence, the risk of infectious complications increases with disease progression and the spectrum of the pathogens also expands, including, in addition to encapsulated bacteria mostly seen in patients with early, untreated CLL, more opportunistic agents such as Pneumocystis jirovecii and mycobacteria in the advanced disease setting (74) . Despite the high overall response rate and disease control achieved with ibrutinib, infections are not absent during longterm treatment with ibrutinib. By a systematic review of prospective trials with ibrutinib for the treatment of lymphoid malignancies, it was found that 56% patients treated with singleagent ibrutinib experienced an infectious complication of any grade. Grade 3-4 infectious adverse events occurred in 26% of the patients; of these, 13% were pneumonia (75) . Of notice, the incidence of fungal opportunistic infections was in the range of 3 to 6% in reported series of patients with lymphoid malignancies, mainly CLL (76) (77) (78) .

In patients with CLL during treatment with ibrutinib, most commonly respiratory tract infections, gastrointestinal/genitourinary and skin infections are observed (60) . Higher infection rates have been reported in R/R patients, with infections ≥ grade 3 reported in more than 30% of the patients (20, 23) compared to 10-20% in those previously untreated (29, 30, 79) . However, the incidence of infections seems to be highest during the first months of treatment to decrease over time (20, 60, 79) .

In the study by Sun et al., the infection rate was significantly higher during the first 6 months of ibrutinib treatment, especially in previously treated patients compared to those receiving ibrutinib as first-line. As discussed above, in this study, despite normal B cells apparently increasing over time, IgG levels decreased, but IgA increased and a significant correlation was observed between increase in IgA levels at 12 months of treatment and infection rate, independent of previous treatment history (60) .

Whether increased infection susceptibility is a class-effect or there are any differences between the different BTKis remains to be elucidated. Since it likely depends on the effect on different pathways and not only on BTK inhibition, it could be speculated that treatment with more selective BTKis, such as acalabrutinib, not affecting the ITK, could result in lower infection rates. However, in the largest phase 3 acalabrutinib trial in the R/R setting, grade ≥3 infectious complications occurred in 23% of the patients (68) . Table 2 summarizes in a simplified way how the effect of BTKi treatment on the different immune cell types can potentially affect susceptibility to different kinds of pathogens.

Suboptimal response to vaccination has been reported in patients with CLL, even in those with indolent and previously untreated disease (80) . In general, seroconversion in CLL patients negatively correlates with previous treatment. Following treatment with anti-CD20 monoclonal antibodies, the serological response to H1N1influenza vaccination was absent for at least 6 months following exposure, recovering 12 months after (81) .

Even if not all Ig subclasses seem to decrease in CLL patients during treatment with ibrutinib (20, 60), probably reflecting the persistence of long-lived plasma cells generated in response to previous infections and vaccinations, it is assumable that longterm BTKi treatment might impair the ability to mount an effective immune response following vaccination, since B-cell maturation relies on functional BTK. In two studies evaluating the seroconversion rate after seasonal influenza vaccine in patients treated with ibrutinib, this was found to be as low as 7% after standard dose (82) and 26% after higher dose (83) .

Pleyer et al. recently reported on the outcome of vaccination with the adjuvanted recombinant hepatitis B (HepB-CpG) and zoster (RZV) vaccines in CLL patients treated with BTKi compared to untreated patients. While no difference was observed between the two patient groups with regard to the serological response to RZV vaccine (41% vs 59%), the de novo humoral response to the HepB-CpG vaccine was significantly lower in BTKi-treated patients (3.8% vs 28%) (84) .

Another study (85) recently confirmed the immunological efficacy of vaccination with adjuvanted recombinant varicella zoster glycoprotein in CLL patients during front-line therapy for ≥3 months with BTKi. Humoral and cellular responses were observed in 75% and 78% of the patients, respectively. However, lower cell-mediated immunogenicity to the same vaccine was recently reported in BTKi-treated CLL patients compared to patients with monoclonal B-cell lymphocytosis (MBL) or untreated CLL (37% vs 73%) (86) .

In another study assessing antibody response to the 13-valent pneumococcal conjugate vaccine (PCV13) in 112 patients with CLL, of which 35 during ibrutinib treatment, immune responses were observed in only nine (8%) patients, eight treatment-naïve and one on front-line ibrutinib. None of the patients vaccinated ≥6 months after chemoimmunotherapy treatment with anti-CD20 monoclonal antibodies developed an immune response (87) . Similarly, no adequate immune response to PCV13 was observed in 4 previously treated patients receiving ibrutinib while it was seen in all 4 previously treated CLL control patients with no ongoing therapy (88) .

During the last decade, treatment with BTKis has significantly improved the prognosis of R/R CLL patients. More extended clinical applications are also awaited, e.g. in the setting of first-line treatment in combination with other biological drugs, such as Bcl-2 antagonists. However, it is now clear that treatment with BTKis broadly affects the adaptive and the innate immune system in patients with CLL. This could explain the relatively high incidence of certain types of infections, such as invasive fungal infections, observed in ibrutinib-treated patients (48, 49) . Infections are higher in the first months of treatment and the incidence decreases with decreasing tumor burden. However, when studying infection susceptibility in CLL patients, many factors should be taken into consideration which make it difficult to compare data from different studies. Among these, biological features of the disease (low vs high-risk) as well as previous and concomitant treatment including steroids, exposure to environmental risk factors, hypogammaglobulinemia with or without ongoing Ig substitution.

With regard to vaccination efficacy, the available data indicate that treatment with BTKi hampers the ability to mount a vaccineinduced immune response against novel antigens. Since T cells are also affected, at least by treatment with ibrutinib, it can be speculated that T-cell dependent B-cell activation is impaired twice, by BTK and ITK inhibition. This issue is of enormous relevance in the light of the ongoing COVID-19 pandemic, especially since patients with CLL may be at high risk of poor outcome if hospitalized due COVID-19 (89, 90) . Further investigation is warranted, including studies on novel vaccination strategies, in patients with CLL. Indeed, it is presumable that patients in different disease phases and with different treatment histories (previous/ongoing) will not respond unanimously to vaccination, and that a patient-tailored vaccination approach might be needed, including temporary suspension of CLL treatment in patients in clinical remission to maximize vaccination efficacy.

Many new inhibitors, which bind reversibly, non-covalently, to the cysteine 481 of the BTK are under development. Indeed, due to safety concerns, irreversible inhibitors are regarded with caution as possible treatment for non-malignant diseases, such as autoimmune ones. Therefore, an alternative binding manner which would allow the compound to inactivate the BTK only temporarily, but with greater potency, is appealing. The expectations from these new compounds are also that they will not cause treatment-resistance due to BTK and/or PLCg2 mutations. However, "off-target" effects are expected to be more consistent, due to the potential binding to multiple structurally related kinases. The challenge is therefore to design reversible covalent binding compounds with more tuneable, on-target residence times (91) than those observed with irreversible inhibitors.

In conclusion, further studies are needed to characterize in depth the biological effects of BTKis to implement new applications of the existing inhibitors in other disease settings or in combination with other drugs, and to guide the development of new, more or less targeted, inhibitors. Moreover, a deeper knowledge of the impact of BTKis on the immune system could guide clinicians in the management of infections and in the prevention thereof.

MP and TM wrote the first version of the manuscript, AÖ edited the first version of the manuscript. All authors contributed to the article and approved the submitted version. 

We thank Ms Leila Relander for excellent secretarial assistance.

From Identification of the BTK Kinase to Effective Management of Leukemia

Bruton's Tyrosine Kinase Is Required for Activation of IkappaB Kinase and Nuclear Factor kappaB in Response to B Cell Receptor Engagement

Phospholipase C-Gamma 2 Couples Bruton's Tyrosine Kinase to the NF-kappaB Signaling Pathway in B Lymphocytes

BTK Inhibition Results in Impaired CXCR4 Chemokine Receptor Surface Expression, Signaling and Function in Chronic Lymphocytic Leukemia

BCR Ligation Induced by IgM Stimulation Results in Gene Expression and Functional Changes Only in IgV H Unmutated Chronic Lymphocytic Leukemia (CLL) Cells

Bruton's Tyrosine Kinase (BTK) Function is Important to the Development and Expansion of Chronic Lymphocytic Leukemia (CLL)

Ibrutinib Inhibits BCR and NF-kappaB Signaling and Reduces Tumor Proliferation in Tissue-Resident Cells of Patients With CLL

Nurselike Cells Express BAFF and APRIL, Which can Promote Survival of Chronic Lymphocytic Leukemia Cells via a Paracrine Pathway Distinct From That of SDF-1alpha

Nurture Versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

Clinical and Biological Implications of Target Occupancy in CLL Treated With the BTK Inhibitor Acalabrutinib

The Lymph Node Microenvironment Promotes B-Cell Receptor Signaling, NF-kappaB Activation, and Tumor Proliferation in Chronic Lymphocytic Leukemia

Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia

Kinetics of CLL Cells in Tissues and Blood During Therapy With the BTK Inhibitor Ibrutinib

Interferon Gamma Inhibits Apoptotic Cell Death in B Cell Chronic Lymphocytic Leukemia

Interleukin 4 Protects Chronic Lymphocytic Leukemic B Cells From Death by Apoptosis and Upregulates Bcl-2 Expression

Chronic Lymphocytic Leukemia B Cells can Express CD40 Ligand and Demonstrate T-Cell Type Costimulatory Capacity

29 Modulates CD40 Signaling in Chronic Lymphocytic Leukemia by Targeting TRAF4: An Axis Affected by BCR Inhibitors

The Bruton Tyrosine Kinase Inhibitor PCI-32765 Thwarts Chronic Lymphocytic Leukemia Cell Survival and Tissue Homing In Vitro and In Vivo

The Clinically Active BTK Inhibitor PCI-32765 Targets B-Cell Receptor-and Chemokine-Controlled Adhesion and Migration in Chronic Lymphocytic Leukemia

Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Ibrutinib Inhibits CD20 Upregulation on CLL B Cells Mediated by the CXCR4/SDF-1 Axis

Guidelines for the Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Report From the International Workshop on Chronic Lymphocytic Leukemia Updating the National Cancer Institute-Working Group

Ibrutinib for Patients With Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion (RESONATE-17): A Phase 2, Open-Label, Multicentre Study

Venetoclax in Relapsed or Refractory Chronic Lymphocytic Leukaemia With 17p Deletion: A Multicentre, Open-Label, Phase 2 Study

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

Ibrutinib as Initial Therapy for Patients With Chronic Lymphocytic Leukemia

BTK (C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

Ibrutinib as Initial Therapy for Elderly Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b/2 Trial

Extended Follow-Up and Impact of High-Risk Prognostic Factors From the Phase 3 RESONATE Study in Patients With Previously Treated CLL/SLL

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

Bruton's Tyrosine Kinase: An Emerging Key Player in Innate Immunity

B-Cell Receptor Pathway Inhibitors Affect CD20 Levels and Impair Antitumor Activity of Anti-CD20 Monoclonal Antibodies

Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK-Cell Effector Function in Patients With Mantle Cell Lymphoma

Differential Regulation of Human NK Cell-Mediated Cytotoxicity by the Tyrosine Kinase Itk

Ibrutinib Antagonizes Rituximab-Dependent NK Cell-Mediated Cytotoxicity

Neutrophil Development and Function Critically Depend on Bruton Tyrosine Kinase in a Mouse Model of X-Linked Agammaglobulinemia

The Bruton Tyrosine Kinase Inhibitor PCI-32765 Ameliorates Autoimmune Arthritis by Inhibition of Multiple Effector Cells

Analysis of the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcgamma Receptor (FcgammaR) Function

Effects of BTK Signalling in Pathogenic Microorganism Infections

Toll-Like Receptor Signaling is Impaired in Dendritic Cells From Patients With X-Linked Agammaglobulinemia

Bruton Tyrosine Kinase Mediates TLR9-Dependent Human Dendritic Cell Activation

A Novel Role for Bruton's Tyrosine Kinase in Hepatocyte Growth Factor-Mediated Immunoregulation of Dendritic Cells

Immunoregulation of Dendritic Cells by the Receptor T Cell Ig and Mucin Protein-3 via Bruton's Tyrosine Kinase and C-Src

Ibrutinib Enhances IL-17 Response by Modulating the Function of Bone Marrow Derived Dendritic Cells

Ibrutinib Blocks Btk-Dependent NF-kB and NFAT Responses in Human Macrophages During Aspergillus Fumigatus Phagocytosis

BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia

Early-Onset Invasive Aspergillosis and Other Fungal Infections in Patients Treated With Ibrutinib

Ibrutinib-Associated Invasive Fungal Diseases in Patients With Chronic Lymphocytic Leukaemia and non-Hodgkin Lymphoma: An Observational Study

Immunomodulatory Effect of Ibrutinib: Reducing the Barrier Against Fungal Infections

The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Exerts Immunomodulatory Effects Through Regulation of Tumor-Infiltrating Macrophages

Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

The Impacts of Zanubrutinib on Immune Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The Role of Tec Family Kinases in Myeloid Cells

The Protein Tyrosine Kinase Tec Regulates Mast Cell Function

Absence of Tec Family Kinases Interleukin-2 Inducible T Cell Kinase (Itk) and Bruton's Tyrosine Kinase (Btk) Severely Impairs Fc epsilonRI-Dependent Mast Cell Responses

The Effect of Ibrutinib on Neutrophil and Gammadelta T Cell Functions

Infectious Complications in Patients With Chronic Lymphocytic Leukemia: Pathogenesis, Spectrum of Infection, and Approaches to Prophylaxis

Immune Defects in Patients With Chronic Lymphocytic Leukemia

Partial Reconstitution of Humoral Immunity and Fewer Infections in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

T Cells in Chronic Lymphocytic Leukemia Display Dysregulated Expression of Immune Checkpoints and Activation Markers

Restricted T Cell Receptor Repertoire in CLL-Like Monoclonal B Cell Lymphocytosis and Early Stage CLL

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy Against CLL

Disruption of In Vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib-Findings From an Investigator-Initiated Phase II Study

Ibrutinib Has Time-Dependent On-and Off-Target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia. Hemasphere (2021)

Ibrutinib Treatment Improves T Cell Number and Function in CLL Patients

Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients With Chronic Lymphocytic Leukemia

Acalabrutinib Monotherapy in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Phase 2 Results

Ibrutinib is an Irreversible Molecular Inhibitor of ITK Driving a Th1-Selective Pressure in T Lymphocytes

Ibrutinib Increases the Clonality of TCR Repertoire in Patients With Chronic Lymphocytic Leukemia

Novel Mouse Model Resistant to Irreversible BTK Inhibitors: A Tool Identifying New Therapeutic Targets and Side Effects

Reduced Airway Hyperresponsiveness and Tracheal Responses During Allergic Asthma in Mice Lacking Tyrosine Kinase Inducible T-Cell Kinase

Changes in T-Cell Subpopulations and Cytokine Network During Early Period of Ibrutinib Therapy in Chronic Lymphocytic Leukemia Patients: The Significant Decrease in T Regulatory Cells Number

Infection and Immunity in Chronic Lymphocytic Leukemia

Systematic Review of Infectious Events With the Bruton Tyrosine Kinase Inhibitor Ibrutinib in the Treatment of Hematologic Malignancies

Incidence of Opportunistic Infections During Ibrutinib Treatment for B-Cell Malignancies

Infections in Patients With Lymphoproliferative Diseases Treated With Target Therapy. Italian Multicentric Retrospective Study Seifem

Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer

Long-Term Efficacy and Safety of First-Line Ibrutinib Treatment for Patients With CLL/ SLL: 5 Years of Follow-Up From the Phase 3 RESONATE-2 Study

Pneumococcal Conjugate Vaccine Triggers a Better Immune Response Than Pneumococcal Polysaccharide Vaccine in Patients With Chronic Lymphocytic Leukemia A Randomized Study by the Swedish CLL Group

Repeated Vaccination is Required to Optimize Seroprotection Against H1N1 in the Immunocompromised Host

Ibrutinib may Impair Serological Responses to Influenza Vaccination

Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib

Effect of Bruton Tyrosine Kinase Inhibitor on Efficacy of Adjuvanted Recombinant Hepatitis B and Zoster Vaccines

Short Term Results of Vaccination With Adjuvanted Recombinant Varicella Zoster Glycoprotein E During Initial BTK Inhibitor Therapy for CLL or Lymphoplasmacytic Lymphoma

Immunogenicity of a Recombinant Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia

Response to the Conjugate Pneumococcal Vaccine (PCV13) in Patients With Chronic Lymphocytic Leukemia (CLL)

Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib

COVID-19 Severity and Mortality in Patients With Chronic Lymphocytic Leukemia: A Joint Study by ERIC, the European Research Initiative on CLL, and CLL Campus

Outcomes of COVID-19 in Patients With CLL: A Multicenter International Experience

The Development of Bruton's Tyrosine Kinase (BTK) Inhibitors From 2012 to 2017: A Mini-Review

Conflict of Interest: MP: Takeda, research support. Beigene, research support. AÖ: Beigene, research support. Astra Zeneca: research support. Gilead: research support. Loxo Oncology: research support